Key Insights

Highlights

Success Rate

91% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

4.4%

3 terminated out of 68 trials

Success Rate

91.4%

+4.9% vs benchmark

Late-Stage Pipeline

7%

5 trials in Phase 3/4

Results Transparency

22%

7 of 32 completed with results

Key Signals

7 with results91% success

Data Visualizations

Phase Distribution

48Total
Not Applicable (21)
P 1 (11)
P 2 (11)
P 3 (4)
P 4 (1)

Trial Status

Completed32
Recruiting15
Unknown13
Terminated3
Active Not Recruiting2
Not Yet Recruiting2

Trial Success Rate

91.4%

Benchmark: 86.5%

Based on 32 completed trials

Clinical Trials (68)

Showing 20 of 20 trials
NCT04197596Phase 1RecruitingPrimary

Treatment of Refractory BK Infections With Related Donor BK Specific Cytotoxic T-cells (CTLs)

NCT07470541Not ApplicableNot Yet Recruiting

Viromes in Infants Presenting With a Septic Syndrome

NCT04230356Phase 2Recruiting

Trial of Scheduled Versus Treatment Administration of Donor-Derived Viral Specific T-cells for Viral Infections After Stem Cell Transplant

NCT04691622Phase 1RecruitingPrimary

Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised Hosts

NCT05603650Not ApplicableRecruiting

Effects of Mouthrinse on the Microbiome of the Oral Cavity and GI Tract

NCT02048332Phase 1Recruiting

Donor-Derived Viral Specific T-cells (VSTs)

NCT02532452Phase 2RecruitingPrimary

Third Party Viral Specific T-cells (VSTs)

NCT05953233Not ApplicableRecruitingPrimary

School Inner City Air Study

NCT06271655Not ApplicableActive Not Recruiting

Rapid Diagnosis of Viral Acute Respiratory Infection to Decrease Unnecessary Antibiotic Utilization in the Emergency Department (RADIATE)

NCT04331275Phase 2Active Not Recruiting

Viral Specific T-cells for Treatment of Viral Infections After Solid Organ Transplant

NCT06149494Phase 2Completed

RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection

NCT04013802Phase 1RecruitingPrimary

TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.

NCT06931002Not ApplicableRecruiting

A Rhinovirus Challenge Study to Investigate Exacerbations and Immune Responses in Bronchiectasis

NCT05246098Recruiting

REVIVe: Frailty, Rehabilitation, and Outcomes in Critically Ill Adult and Pediatric Survivors of COVID-19 or ARI

NCT05467007Not ApplicableCompletedPrimary

Urgent Care Management of Respiratory Illness Enabled With Novel Testing Pathway

NCT03594981Phase 1RecruitingPrimary

Adoptive Cord Blood Immunotherapy for EBV, CMV, BKV and Adenovirus Reactivation/Infection or Prophylaxis

NCT06488118Not ApplicableRecruiting

Lung Immune Challenge Study: Controlled Exposure to Inhaled Resiquimod (R848)

NCT04267809Phase 2Completed

Modulate Cellular Stress in the Immune Cells to Reduce Rate of Symptomatic Viral Infection

NCT06025682Recruiting

Retrospective Observational Study on Infective Complications and Outcome of Patients With ALL Treated With INO

NCT05671159Not ApplicableRecruitingPrimary

COMPArative Study of the Consequence on innaTe Immune Response du to Bacterial or Viral Infection in Patients Admitted to Intensive Care Unit

Scroll to load more

Research Network

Activity Timeline